We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

GSK aftermath: pharma grapples with compliance issues

News

Executive Summary

GlaxoSmithKline's Chinese bribery scandal – which last month ended with the UK major being fined a record sum of nearly $490 million – has left the pharma industry pondering its next steps to meet a rising bar and the soaring costs of compliance1.